Sesame Summit 2026 – application open

Rivia raises €13M to bring agentic AI to clinical trials

The application of AI in clinical trials is rapidly reshaping the pharmaceutical development landscape, as biotech companies and contract research organisations grapple with spiralling data complexity and mounting pressure to accelerate drug approvals. Zurich-based Rivia has secured €13 million in Series A funding to scale its agentic data platform, which aims to transform how clinical trial operations teams manage the vast volumes of data generated during modern drug development programmes.

The round, led by European venture capital firm Earlybird through its dedicated health fund, brings Rivia’s total funding to approximately €16 million following a €3 million seed round in 2024. New investor Defiant joined the round alongside returning backers Speedinvest, Amino Collective and Nina Capital. The fresh capital will be deployed to expand Rivia’s teams in Zurich and Boston, and to accelerate the rollout of its suite of embedded AI agents designed to automate clinical trial workflows.

Earlybird Health leads investment in agentic AI for clinical trials

The Series A was led by Earlybird Health, the healthcare-focused arm of pan-European venture firm Earlybird, which manages a dedicated €173 million health fund backing companies that are transforming patient outcomes through technology. The investment underscores growing investor confidence in AI-powered infrastructure for the life sciences sector, particularly platforms that address the operational bottleneck of clinical data management rather than drug discovery alone.

Founded in 2022 by Erik Scalfaro and Tiago Kieliger, Rivia was born from first-hand frustration with the fragmented data landscape in pharmaceutical development. Scalfaro, who spent a decade in the pharma industry, has spoken of clinical operations as a world dominated by manual spreadsheet work — downloading hundreds of Excel files, formatting data, and consolidating information rather than focusing on patient outcomes. Kieliger, previously a cybersecurity engineer for the Swiss defence department, brought deep technical expertise in building secure, scalable data infrastructure.

Rivia’s platform serves as what the company calls a reusable intelligence layer for clinical trials. Its data engine integrates thousands of heterogeneous data files in real time, applies trial-specific scientific logic through a proprietary library of reusable configurations, and feeds harmonised data directly into operational review workflows. The company currently supports 40 clinical trials across Europe and the United States, handling data volumes that have grown over 400 per cent in the past decade.

From data engine to agentic AI in clinical trial operations

On this data foundation, Rivia is now launching a suite of embedded AI agents designed to automate high-impact clinical workflows. The company’s first agent, Spark, converts natural-language queries into publication-grade clinical visualisations instantly, eliminating the manual effort traditionally required to produce trial analytics. Additional agents are being deployed for proactive data quality monitoring and oversight workflows, enabling earlier detection of deviations and intelligent prioritisation of issues across trial sites.

The broader market opportunity is substantial. The global AI in clinical trials market is estimated at approximately $1.5 billion in 2026 and is projected to reach $18–20 billion by the end of the next decade, driven by increasing data complexity and regulatory pressure for faster, more efficient trial execution. Rivia’s ambition is to reduce clinical trial costs by up to 50 per cent by replacing manual processes with scalable agentic systems — a proposition that resonates strongly in an industry where the average cost of bringing a new drug to market continues to exceed $2 billion.

The strategic decision to build the data infrastructure layer before deploying AI agents is central to Rivia’s thesis. As co-founder Kieliger has noted, AI and agents can deliver significant value for clinical trials, but the limiting factor remains the underlying data infrastructure. By establishing a robust intelligence layer that aggregates data across sources and models the specific scientific logic behind each trial, Rivia has created the foundation upon which its agentic capabilities can operate with precision and reliability.

With this latest funding, Rivia is well-positioned to capitalise on the accelerating adoption of AI in clinical trials across Europe and the United States. The combination of a proven data platform, embedded AI agents, and backing from specialist healthcare investors suggests the Zurich-based company is building for long-term impact in a sector where efficiency gains translate directly into faster patient access to life-saving therapies.

Summary

  • Company: Rivia
  • Headquarters: Zurich, Switzerland
  • Founded: 2022
  • Round: Series A
  • Amount: €13 million ($15 million)
  • Lead Investor: Earlybird Health
  • Other Investors: Defiant, Speedinvest, Amino Collective, Nina Capital
  • Use of Funds: Team expansion in Zurich and Boston, rollout of embedded AI agents for clinical trial workflows

you might also like

Fundraising 4 hours ago

London-based AI laboratory Ineffable Intelligence has emerged from stealth with a $1.1 billion seed round at a $5.1 billion post-money valuation, the company confirmed on 27 April 2026. The financing is the largest seed round ever raised by a European company and one of the largest first-money-in rounds in the global history of artificial intelligence. The round was co-led by Sequoia Capital and Lightspeed Venture Partners. Participating investors included Nvidia, DST Global, Index Ventures, Google, and the UK Sovereign AI Fund, the British government’s recently established vehicle for backing strategic AI capacity on home soil. A bet on a different path to general intelligence Ineffable Intelligence was founded in 2025 by David Silver, the former Vice President of Reinforcement Learning at Google DeepMind and the principal architect of AlphaGo, AlphaZero and AlphaStar. He is joined by three further DeepMind alumni: Wojciech Czarnecki, Lasse Espeholt and Junhyuk Oh. All four have spent the past decade at the frontier of reinforcement learning research, the discipline behind some of the most consequential demonstrations of machine learning over the past ten years. The company describes its objective as building a “superlearner” — an AI system capable of acquiring knowledge directly from its own experience rather than from human-generated text or imagery. “Our mission is to make first contact with superintelligence,” Silver said in a statement accompanying the launch. “We are creating a superlearner that discovers all knowledge from its own experience, from elementary motor skills through to profound intellectual breakthroughs.” The framing is a deliberate departure from the dominant industry trajectory. Most leading AI laboratories, including OpenAI, Anthropic and Google DeepMind itself, have built large language models trained primarily on the corpus of the internet, then refined that training with human feedback. Ineffable’s wager is that the marginal returns on scaling text-based pretraining are diminishing and that the next leap in capability will come from agents that learn endlessly from the consequences of their own actions, in much the same way AlphaZero learnt the game of Go without studying any human matches. Why $1.1 billion at seed The size of the round is unusual even by the inflated standards of the 2026 AI capital cycle. Two factors appear to explain it. First, frontier reinforcement learning at the scale Ineffable describes is computationally extraordinarily expensive: the company will need to operate vast simulation environments and train very large models against them, an undertaking that consumes capital at a rate closer to physical R&D than to traditional software. Second, the round signals a strategic move by Europe’s investor and policy ecosystems to retain the most ambitious AI researchers on the continent. The presence of the UK Sovereign AI Fund alongside Sequoia, Lightspeed and Nvidia is the clearest expression of that intent. The British government has publicly framed the investment as a bet on breakthrough AI that “can discover new knowledge”, positioning the country as a willing co-investor in domestic frontier laboratories. For Ineffable, the implication is access not only to capital but to compute, regulatory engagement and the still-resilient academic talent base around UCL, Oxford, Cambridge and Imperial. Founder pledge of historic scale Alongside the funding announcement, Silver disclosed that he is committing 100 per cent of any personal proceeds from his Ineffable equity to charity via the Founders Pledge network — described by the organisation as the largest pledge in its history. At the round’s $5.1 billion valuation, that commitment could ultimately exceed several billion dollars if the company succeeds. It is a meaningful gesture in a sector where the reputational stakes around concentrated AI wealth are escalating, and one likely to be referenced in subsequent founder-led commitments. Implications for the European AI landscape Ineffable’s emergence reshapes the European AI map in three concrete ways. It establishes London as the home of the continent’s largest-ever seed-stage company, complicating Paris’s recent narrative of frontier-AI primacy after Mistral’s earlier rounds. It validates a thesis — that reinforcement learning, not transformer scaling, is the next frontier — that has lately been losing capital share to language-model incumbents. And it confirms that the UK government is now willing to act as a balance-sheet co-investor in domestic AI laboratories, a posture much closer to the French model than to the predominantly grant-based regimes elsewhere in Europe. The execution risk is non-trivial. Reinforcement learning at frontier scale has historically required years of careful environment design before producing competitive systems, and Ineffable’s “first contact” framing sets a high bar against which it will be judged. But for now, with a billion dollars on the balance sheet, four of the discipline’s most accomplished researchers in the founding team and a sovereign co-investor at its back, Ineffable Intelligence is the most heavily resourced new entrant in the European AI cycle. Sesamers covers European fundraising rounds across deeptech, fintech and AI. Source: tech.eu.

Fundraising 5 days ago

Belfast's Cloudsmith has raised $72M Series C led by TCV, with Insight Partners participating, to expand its artifact management platform and secure the AI-era software supply chain.

Fundraising 5 days ago

Berlin’s VREY has raised €3.3M seed led by Rubio Impact Ventures to roll out rooftop solar software for Germany’s multi-family buildings.

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.